DMO-PHP Stats & Data

• Identity confusion exists between dimethoxy pyrrolidinophenones: both 3',4'-dimethoxy‑α‑PHP (hexanone) and 3,4‑dimethoxy‑α‑PVP (pentanone) circulate online under overlapping names (e.g., “3,4‑DMPV”). Mislabeling raises dosing risk; confirm with instrumental drug checking when possible.

• PubChem lists entries for both dimethoxy α‑PVP and 3',4'-dimethoxy‑α‑PHP, supporting the presence of both scaffolds on the market; do not assume which you have based on vendor naming or reagent tests alone.

• Reagent kits have limited specificity for cathinones; Liebermann/Simons patterns can suggest a cathinone but cannot distinguish ring/side‑chain variants—avoid making dosage decisions from reagents; use lab drug checking (GC/MS, LC‑MS).

• As a pyrrolidinophenone, expected pharmacology is potent dopamine/norepinephrine transporter inhibition with minimal SERT activity; risks include tachycardia, hypertension, vasoconstriction (cold extremities), anxiety/paranoia, hyperthermia and, at high/extended doses, rhabdomyolysis.

• Acute management (medical setting): benzodiazepines are first‑line for sympathomimetic toxicity (agitation, hypertension, hyperthermia, seizures). External cooling for hyperthermia; avoid self‑treating stimulant symptoms with beta‑blockers without clinical oversight due to potential unopposed α‑effects.

• Chronic/behavioral risks: strong craving/redosing loops, sleep deprivation, weight loss, depressive ‘crash’, and stimulant psychosis—risk increases with binges/multi‑day use, as seen with MDPV/α‑PVP cases.

• Routes: oral has the gentlest profile; insufflation can increase BP/vasoconstriction and irritate sinuses; inhalation (vaporizing) causes very rapid spikes, harsh smoke, and the highest compulsion—prefer oral if using at all.

• Harm reduction: use an accurate 1 mg‑resolution scale; consider volumetric dosing for sub‑10 mg accuracy. Plan a hard cap on total session dose and number of redoses; set a time limit. Keep cool, avoid strenuous activity, sip electrolytes, and schedule nutrition and sleep.

• Polysubstance & mis-sold risks are common in the cathinone market (e.g., α‑PVP or NEP sold as ‘3‑MMC’). Use accredited drug‑checking services where available; start with allergy test doses from any new batch.

• No human pharmacokinetic data for DMO‑PHP specifically; half‑life is inferred from related α‑PHP/α‑PVP analogs; large inter‑individual variability should be expected.